Risk factors for depression and fatigue among survivors of hematopoietic cell transplantation
Menée aux Etats-Unis à partir de données portant sur 1 869 patients ayant survécu à un cancer traité à l'aide d'une greffe de cellules souches hématopoïétiques (âge moyen : 56 ans), cette étude analyse les facteurs cliniques et sociodémographiques associés au risque de dépression et de fatigue
BACKGROUND Patients treated with hematopoietic cell transplantation (HCT) often experience depression and fatigue but analyses to determine risk factors have typically lacked statistical power. The current study examined sociodemographic and clinical risk factors for depression and fatigue in a large cohort of survivors of HCT. METHODS Measures of depression and fatigue were included in an annual survey of HCT recipients that also included self-reported sociodemographic and health information. Patient clinical characteristics were obtained from the clinical database. RESULTS The sample consisted of 1869 recipients (with a mean age of 56 years; 53% male) who were a mean of 13 years (allogeneic recipients) and 6 years (autologous recipients) from HCT. Moderate to severe depression was reported by 13% of participants; moderate to severe fatigue was reported by 42%. Among allogeneic recipients, female sex, younger age, current presence of chronic pain, and current patient-reported severity of chronic graft-versus-host disease were found to be independently associated with greater depression whereas female sex, current presence of chronic pain, and current severity of chronic graft-versus-host disease were independently associated with greater fatigue (P values <.01). Among autologous recipients, younger age and current presence of chronic pain were found to be independently associated with both greater depression and greater fatigue (P values <.01). CONCLUSIONS Rates of depression and fatigue in this group of survivors suggest a high symptom burden. Better screening, referral, and interventions are needed. Cancer 2016. © 2016 American Cancer Society.
Cancer 2016